Optos PLC announced the presentation of more than 50 positive clinical studies at ARVO. The clinical studies involved clinical sites from 49 academic institutes in 10 countries. In total, 3,324 patients and 5,376 eyes were studied to investigate the importance of Optos ultra-widefield imaging. The researchers identified positive clinical evidence in 25 different eye diseases using Optos ultra-widefield and optical coherence tomography medical technology.
The clinical studies presented include a study of 745 patients by a team of researchers led by Shachar Tauber, MD, Mercy Hospital, Springfield, Missouri. The team investigated an ocular teleheath screening program for detecting diseases including diabetic retinopathy at a stage when treatment can prevent visual loss. The Ocular Telehealth Program was implemented in four primary care physician (PCP) clinics within an integrated tertiary care health system. The program includes non-invasive non-mydriatic ultra-widefield optomap retinal images taken of diabetic patients while in the PCP offices. The results found 18% referral rate for sight threatening disease, over one-third of these patients were referred due to diabetic eye disease.
Dr. Tauber said "We know that traditionally only 50% of patients with diabetes have annual eye exams. This study reached out further, to Primary Care to identify diabetic eye disease in these needy patients and save sight. Using integrated electronic health records with Optos ultra-widefield imaging we had near instantaneous communication with the patient's primary care doctor to ensure prompt management. I believe the ability to educate our patients will impact the course of this disease. Ophthalmology has to work hand in hand with Primary Care Physicians and the Optos image gives us the tool”
Another study led by Michael Singer, MD, at Medical Centre Ophthalmology Associates, San Antonio, Texas captured optomap retinal images of 21 patients to evaluate the extent of peripheral retinal disease in patients with retinal vein occlusions to determine response and requirement for re-treatment of macular edema with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) and/or dexamethasone intravitreal implants. The study found a statistically significant correlation of the extent of peripheral retinal disease when macular edema was present. The researchers concluded that these increased areas may drive VEGF production and result in more severe macular edema.
Commenting on the results of his study which investigated using Optos technology to predict treatment response, Dr. Singer, said "With Optos ultra-widefield images, for the first time we have the chance to see the whole of the retina, we never saw this before. It is changing the way we treat our patients as only with Optos can we save more retina and determine when to treat with injections and laser. For our patients' sight this technology is groundbreaking.”
Roy Davis, CEO of Optos, said “These results underpin our vision to drive our clinical evidence even further. We are now demonstrating to Clinicians the ability to see more, refer more, and treat more and importantly to understand more about the extent of eye disease. Further studies are already underway with leading Investigators and with Pharmaceutical companies to validate our findings.”